COZADD BRUCE C 4
4 · Jazz Pharmaceuticals plc · Filed Mar 4, 2026
Insider Transaction Report
Form 4
COZADD BRUCE C
Director
Transactions
- Sale
Ordinary Shares
[F1][F2]2026-03-03$186.09/sh−3,159$587,843→ 408,637 total - Sale
Ordinary Shares
[F1][F3]2026-03-03$186.73/sh−2,608$487,002→ 406,029 total - Sale
Ordinary Shares
[F1][F4]2026-03-03$187.84/sh−233$43,768→ 405,796 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $185.500 to $186.4207. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F3]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.500 to $187.4693. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F4]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $187.7783 to $188.1678 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Signature
By: /s/Paz Dizon, as attorney in fact For: Bruce C. Cozadd|2026-03-04